Clinical depiction, treatment and long term follow up characterization of a group of enthesitis related arthritis - juvenile idiopathic arthritis patients from a spanish pediatric tertiary hospital by Samuel Baldizon et al.
POSTER PRESENTATION Open Access
Clinical depiction, treatment and long term
follow up characterization of a group of
enthesitis related arthritis - juvenile idiopathic
arthritis patients from a spanish pediatric
tertiary hospital
Samuel Hernandez Baldizon1*, Vicente Torrente-Segarra1, Estibaliz Iglesias1, Rosa Bou1, Judith Sanchez Manubens1,
Joan Calzada Hernandez1, Lilian López Núñez2, Clara Giménez- Roca1, Silvia Ricart1, Joan Nolla Solé3,
Jordi Anton Lopez1
From 21st European Pediatric Rheumatology (PReS) Congress
Belgrade, Serbia. 17-21 September 2014
Introduction
Enthesitis related arthritis (ERA) is a subtype of Juvenile
Idiopathic Arthritis (JIA) that affects children >6 years
of age. It presents with enthesitis, uveitis, peripheral and
axial arthritis. It´s one of the less frequent subtypes of
JIA. Data is scarse involving follow up and outcomes.
Objectives
Describe a case series of JIA-ERA patients of a Spanish
cohort in a tertiary pediatric hospital. Report response to
oral (OR) and subcutaneous (SC) methotrexate (MTX) in
insufficient/non-responders to NSAID/intra-articular
steroid infiltrations in these patients. Relate the persis-
tence of symptoms on follow-up and course of treatment.
Methods
Retrospective and observational.Inclusion criteria:
Edmonton classification criteria for ERA-JIA. Variables:
age, sex, HLA-B27, date and delay of diagnosis, onset of
symptoms, classification, start/finish of date of OR
MTX, start/finish date of MTX SC, date of start of bio-
logic treatment (as a variable of MTX inefficacy).
Articular activity: number of swollen joints (NSJ) and
number of painful joints (NPJ). Prospective data will be
collected starting January 2014 of all ERA-JIA patients
visited in our Unit. Local ethics committee approval was
acquired.
Results
11 patients all of which were male (100%), mean age of
15.3 (SD 4.6), age of first symptom 11.2, (SD 2.4), age of
diagnosis 11.6 years (SD 2.3), delay in diagnosis 4.7
months (SD 6.3), follow up 55.6 months (SD 42.2). 90%
were HLA-B27positive. The rest of the clinical data are
summed up on table 1. Number of painful joints (NPJ)
varied from 0-4, number of swollen joints (NSJ) between
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Table 1
Joint activity NPJ at onset NPJ at end of follow up NSJ at onset NSJ at end of follow up
Average 1 0 2.82 0.13
Standard deviation 1.34 0.00 3.28 0.35
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0 and 8. 90.9% (10 patients) required MTX. Six received
OR MTX (54.5%), 4 of these patients switched to SC
MTX (66.7%) due to inefficacy. A total of 8 of 11 patients
received SC MTX. The average dose of MTX was 14.6
mg/week (SD 3.9). Two (20%) patients continued MTX
on transition to the adult rheumatology clinic. The aver-
age time on MTX was 13.1 months (SD 7.6). One patient
suspended treatment with MTX because of digestive
intolerance and another because of inefficacy. One
patient (9%) started Etanercept because of partial
response to both OR and SCMTX.
Conclusion
Patients had a mean age of 11 years at time of diagnosis,
are male, HLA-B27 positive and have low level joint activ-
ity. The majority of patients that started OR MTX
switched to SC MTX due to inefficacy or insufficient
response, with a mean weekly dose of 15mg/weekSC
MTX. The rate of side effects was low (<10%). Several
patients required active treatment (DMARD/biologic)
after 4 years of follow-up. Our findings should be taken
with a grain of salt as this analysis is preliminary and we





1Pediatric Rheumatology Unit, Pediatrics Department, Hospital Sant Joan de
Deu, Barcelona, Spain. 2Department of Rheumatology, Hospital del Mar,
Barcelona, Spain. 3Department of Rheumatology, Hospital de Bellvitge,
Barcelona, Spain.
Published: 17 September 2014
doi:10.1186/1546-0096-12-S1-P181
Cite this article as: Baldizon et al.: Clinical depiction, treatment and long
term follow up characterization of a group of enthesitis related
arthritis - juvenile idiopathic arthritis patients from a spanish pediatric
tertiary hospital. Pediatric Rheumatology 2014 12(Suppl 1):P181.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baldizon et al. Pediatric Rheumatology 2014, 12(Suppl 1):P181
http://www.ped-rheum.com/content/12/S1/P181
Page 2 of 2
